Aiming at the domestic hundreds of billions of ophthalmology market, Chinese and foreign pharmaceutical companies to accelerate the layout

"Pharmaceutical Network Industry Dynamics" Recently, the Signing Ceremony of the Memorandum of Understanding on the "China Medical Association Eye Science Branch - Singtian Pharmaceutical Ophthalmologist Scholarship" co-sponsored by the Ophthalmology Branch of the Chinese Medical Association and Suntian Pharmaceutical Co., Ltd. was held online.
signing of the memorandum of understanding marks the official launch of a new round of "Participation Scholarships", which will be used for professional training and continuing education of Chinese ophthalmologists.
understand that Singtian Pharmaceuticals is Japan's leading ophthalmology prescription drug market.
more than 120 years since its inception, we have been committed to the research and development of products in the field of ophthalmology, and are the representative companies in the field of ophthalmology prescription drugs in Japan.
entered China in 1988 through the export and sale of agent stores to the Chinese market, and has been increasing its investment and development efforts in China for many years.
now, China's business is showing a rapid growth trend, accounting for 60% of the total in other parts of Asia except Japan, and the synthetic antibacterial eye drops market in Chinese hospitals has reached a high market share of 45%.
note that in recent years, the movement of Tiantian Pharmaceuticals in the Chinese market has become more frequent, there has been a substantial expansion of the action.
Today, in May this year, the high-speed filling line of Sakeng Pharmaceuticals (China) was officially put into commercial production, directly increasing the existing production speed by nearly six times, allowing the Suzhou plant's production capacity to triple in a short period of time.
addition, Sant'an is also building a new plant with a construction area of 120,000 square meters and an annual production capacity of 1 billion pharmaceuticals in Suzhou Industrial Park.
believes that behind Ssingtian Pharmaceuticals' expanding capacity, in addition to demonstrating Ssingtian's determination and confidence to expand its business in China.
, but also to further meet the growing population of eye disease patients in China, as well as high-quality eye drops continue to grow rapidly market demand.
It is understood that due to the aging of the population, widespread use of electronic products, improper use of the eye and other lifestyle changes, the incidence of various types of eye diseases in China is increasing year by year, eye infections, conjunctivitis, macular degeneration, dry eye disease and other eye diseases increased significantly, the demand for medication has continued to grow.
2013-2017, China's ophthalmology market grew from 46.7 billion yuan to 86.6 billion yuan, with a compound annual growth rate of 16.7%, according to data released last year.
, some research reports predict that in 2018-2022, the size of the domestic ophthalmology market will continue to grow at a rate of about 14%, the total size will exceed 100 billion.
huge market size, of course, has also attracted countless enterprises to add code.
The author combed and found that, in addition to Japan, Novartic, the United States, such as foreign pharmaceutical giants, as well as the rapid rise of domestic ophthalmology drug companies, Kanghong Pharmaceuticals, Allison Pharmaceuticals, Xingqi Eye Medicine, Zhuhai Yisheng, etc. are in the plus-code card position.
, such as Hengrui Pharmaceuticals, in November 2019, it spent heavily to introduce two innovative ophthalmology drugs in Germany to enter the ophthalmology market.
it is understood that the two drugs are mainly used for dry eye disease, after the agreement, Hengrui will be the two products in China's clinical development, production and marketing rights.
, in China's ophthalmology drug market, foreign enterprises with strong technical strength and strong brand promotion efforts still firmly occupy the leading position in the ophthalmology hospital market.
future, in order to occupy more market share in the eye drug market, domestic enterprises also need to catch up and accelerate the pace of innovation and research and development.